CCNT2-AS1: A Promising Drug Target / Biomarker (G100129961)
CCNT2-AS1: A Promising Drug Target / Biomarker
The cancer cell-navigated intracellular transport (CCNT2) system is a complex protein that plays a crucial role in the delivery of molecules to various cellular compartments.CCNT2 is a protein that is expressed in most tissues of the body and is involved in the transport of a wide variety of molecules, including small molecules, ions, and vesicles. The CCNT2 system is also involved in the delivery of neurons to their target cells during development and in the regulation of tissue repair processes.
Recent studies have identified CCNT2 as a potential drug target and a biomarker for various diseases, including cancer.CCNT2 has been shown to be involved in the delivery of cancer cells to their target cells, which may make it an attractive target for cancer therapies. Additionally, studies have also shown that CCNT2 is involved in the regulation of cell death, which may make it a useful target for diseases that are characterized by persistent cell survival.
Drugs that target CCNT2 have been shown to be effective in treating various diseases, including cancer.For example, a drug called AEA1241 is currently being developed as a potential cancer treatment.AEA1241 is a small molecule that binds to the C-terminus of CCNT2 and inhibits its function as a transport protein.Studies have shown that AEA1241 is effective in treating various types of cancer, including lung, breast, and ovarian cancers.
Another drug that targets CCNT2 is called NX-4481.NX-4481 is a small molecule that binds to the N-terminus of CCNT2 and inhibits its function as a transport protein.Studies have shown that NX-4481 is effective in treating various types of cancer, including lung, breast, and ovarian cancers.
In addition to these drugs, researchers are also studying the potential of other small molecules as targets for CCNT2.One of the most promising of these molecules is called RG7848.RG7848 is a small molecule that binds to the C-terminus of CCNT2 and inhibits its function as a transport protein.Studies have shown that RG7848 is effective in treating various types of cancer, including lung, breast, and ovarian cancers.
Another potential drug target for CCNT2 is the protein known as CSN6.CSN6 is a protein that is expressed in most tissues of the body and is involved in the transport of various molecules, including the protein CCNT2.Studies have shown that CSN6 can interact with CCNT2 and may be a potential drug target for CCNT2-mediated processes.
In conclusion, CCNT2 is a protein that is involved in the delivery of molecules to various cellular compartments.Recent studies have identified CCNT2 as a potential drug target and a biomarker for various diseases, including cancer.The use of drugs that target CCNT2, such as AEA1241, NX-4481, and RG7848, has shown to be effective in treating various types of cancer.Additionally, researchers are also studying the potential of other small molecules as targets for CCNT2. Further research is needed to fully understand the role of CCNT2 in disease and to develop effective treatments.
Protein Name: CCNT2 Antisense RNA 1
The "CCNT2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCNT2-AS1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40
